Gilead and Galapagos will continue to investigate the potential for filgotinib to support patients living with Inflammatory Bowel Disease... Dec 16
Vaccines will be as challenging to deliver as they were to develop, warn experts ... Dec 16
Fortress Biotech declares US FDA has granted breakthrough therapy designation for CUTX-101, Copper Histidinate, for the treatment of Menkes Disease ... Dec 16
Shorter infusion time will further improve the twice-yearly treatment experience for OCREVUS, the only B-cell therapy for relapsing and primary progressive MS with ... Dec 15
-Advertisements-